Expression of EEF1A1 Is Associated with Prognosis of Patients with Colon Adenocarcinoma

Abstract

Background: The prognostic role of the translational factor, elongation factor-1 alpha 1 (EEF1A1), in colon cancer is unclear. Objectives: The present study aimed to investigate the expression of EEF1A in tissues obtained from patients with stage II and III colon cancer and analyze its association with patient prognosis. Methods: A total of 281 patients with colon cancer who underwent curative resection were analyzed according to EEF1A1 expression. Results: The five-year overall survival in the high-EEF1A1 group was 87.7%, whereas it was 65.6% in the low-EEF1A1 expression group (hazard ratio (HR) 2.47, 95% confidence interval (CI) 1.38–4.44, p = 0.002). The five-year disease-free survival of patients with high EEF1A1 expression was 82.5%, which was longer than the rate of 55.4% observed for patients with low EEF1A1 expression (HR 2.94, 95% CI 1.72–5.04, p < 0.001). Univariate Cox regression analysis indicated that age, preoperative carcinoembryonic antigen level, adjuvant treatment, total number of metastatic lymph nodes, and EEF1A1 expression level were significant prognostic factors for death. In multivariate analysis, expression of EEF1A1 was an independent prognostic factor associated with death (HR 3.01, 95% CI 1.636–5.543, p < 0.001). EEF1A1 expression was also an independent prognostic factor for disease-free survival in multivariate analysis (HR 2.54, 95% CI 1.459–4.434, p < 0.001). Conclusions: Our study demonstrated that high expression of EEF1A1 has a favorable prognostic effect on patients with colon adenocarcinoma.

Identification and Interaction Analysis of Molecular Markers in Pancreatic Ductal Adenocarcinoma by Integrated Bioinformatics Analysis and Molecular Docking Experiments

“…PLA2G4A [86], FGG (fibrinogen gamma chain) [87] and TYMS (thymidylatesynthetase) [88] have been demonstrated to be up regulated in cancer, but these genes might be liable for progression of PDAC. RAB32 [89], SEPTIN4 [90], TPM2 [91], ACOT7 [92], PRTFDC1 [93], CABLES1 [94], HLA-DMB [95], PTPRC (protein tyrosine phosphatase receptor type C) [96], CD5 [97], CD6 [97], MS4A1 [98], CD22 [99], CD27 [100], MRC2 [101], CLEC2D [102], EEF1A1 [103] and APOB (apolipoprotein B) [104] played a predominant role in the cancer progression, but these genes might be associated with development of PDAC. Jung et al [105] found that SMPD1 stimulates the drug resistance in colorectal cancer, but this gene might be linked with development of PDAC.…”

“…Then, GO [96], CD5 [97], CD6 [97], MS4A1 [98], CD22 [99], CD27 [100], MRC2 [101], CLEC2D [102], EEF1A1 [103] and APOB (apolipoprotein B) [104] played a predominant role in the cancer progression, but these genes might be associated with development of PDAC. Jung et al [105] found that SMPD1 stimulates the drug resistance in colorectal cancer, but this gene might be linked with development of PDAC.…”

An overview on tumor treating fields (TTFields) technology as a new potential subsidiary biophysical treatment for COVID-19

“…Additionally, it has high expression in tumors. Hence, its high level may be considered as a tumor marker [ 78 – 80 ].…”

Expression and Clinical Value of Eukaryotic Translation Elongation Factor 1A1 (EEF1A1) in Diffuse Large B Cell Lymphoma

“…High expression of EEF1A1 was reported to predict a favorable overall survival of colon adenocarcinoma patients. 15 According to the data by Lin et al, EEF1A1 mRNA levels are reduced in clinical breast ductal carcinoma specimens. Underexpression of EEF1A1 mRNA predicts poor prognosis for estrogen receptor-positive cancer patients.…”